{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:23:42Z","timestamp":1787063022005,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ijrobp.2020.06.020","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T03:34:31Z","timestamp":1593228871000},"page":"979-986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes"],"prefix":"10.1016","volume":"108","author":[{"given":"Joseph A.","family":"Bovi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Prah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber A.","family":"Retzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Schmainda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy S.","family":"Marszalkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade M.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika L.","family":"Siker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2020.06.020_bib1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ijrobp.2009.11.058","article-title":"Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy","volume":"79","author":"Adkison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib2","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.prro.2017.04.003","article-title":"Intensity modulated radiation therapy with pulsed reduced dose rate as a reirradiation strategy for recurrent central nervous system tumors: an institutional series and literature review","volume":"7","author":"Murphy","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib3","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib4","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for\u00a0glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/COC.0000000000000380","article-title":"Outcomes for anaplastic glioma treated with radiation therapy with or without concurrent temozolomide","volume":"41","author":"McTyre","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib7","first-page":"252","article-title":"Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813","volume":"19","author":"Chang","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib8","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1158\/1078-0432.CCR-11-1274","article-title":"A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951","volume":"17","author":"van den Bent","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib9","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.ejca.2007.12.005","article-title":"Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)","volume":"44","author":"Hildebrand","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.ijrobp.2003.08.024","article-title":"Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404","volume":"58","author":"Prados","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-015-1845-7","article-title":"Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131","volume":"124","author":"Vogelbaum","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","article-title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: A phase 3, randomised, open-label intergroup study","volume":"390","author":"van den Bent","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-007-9329-z","article-title":"Pulsed reduced dose-rate radiotherapy. Case report: A novel re-treatment strategy in the management of recurrent glioblastoma multiforme","volume":"83","author":"Cannon","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1259\/bjr\/15764945","article-title":"On the possible increase in local tumour\u00a0control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule","volume":"80","author":"Tom\u00e9","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11060-014-1363-z","article-title":"Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab","volume":"117","author":"Magnuson","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib16","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1016\/j.ijrobp.2016.06.906","article-title":"Pulsed reduced dose rate reirradiation (PRDR) using modulated arc (mARC) intensity modulated radiation therapy for recurrent gliomas: Initial clinical outcomes of a novel technique [Abstract]","volume":"96","author":"Siker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2010.10.057","article-title":"Semicontinuous low-dose-rate teletherapy for the treatment of recurrent glial brain tumors: Final report of a phase I\/II study","volume":"82","author":"Siker","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus\u00a0lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib19","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00066-011-0055-2","article-title":"Radiation treatment parameters for re-irradiation of malignant glioma","volume":"188","author":"Niyazi","year":"2012","journal-title":"Strahlenther Onkol"},{"issue":"3, Supplement","key":"10.1016\/j.ijrobp.2020.06.020_bib21","doi-asserted-by":"crossref","first-page":"E112","DOI":"10.1016\/j.ijrobp.2015.07.834","article-title":"Pulsed reduced dose rate reirradiation for recurrent primary central nervous system tumors [Abstract]","volume":"93","author":"Murphy","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/153303461000900409","article-title":"Reirradiation of glioblastoma through the use of a reduced dose rate on a tomotherapy unit","volume":"9","author":"Rasmussen","year":"2010","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ijrobp.2003.12.029","article-title":"Low dose hyper-radiosensitivity in metastatic tumors","volume":"59","author":"Harney","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib24","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/0360-3016(90)90350-S","article-title":"Radioresponse of human astrocytic tumors across grade as a function of acute and chronic irradiation","volume":"19","author":"Schultz","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ijrobp.2011.01.045","article-title":"MicroPET\/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiation","volume":"80","author":"Park","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","article-title":"Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas","volume":"75","author":"Gutin","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169292","article-title":"Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: A correlation with histopathology","volume":"12","author":"Eidel","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11060-018-2989-z","article-title":"Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?","volume":"140","author":"Palmer","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2020.06.020_bib29","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.ijrobp.2019.06.539","article-title":"Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology\/RTOG 1205): Initial Outcomes and RT Plan Quality Report","volume":"105","author":"Tsien","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl_5","key":"10.1016\/j.ijrobp.2020.06.020_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noy129.041","article-title":"Large volume re-irradiation is a viable option in patients with recurrent refractory glioblastoma [Abstract]","volume":"20","author":"Back","year":"2018","journal-title":"Neuro-Oncology"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162031261X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162031261X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:55:53Z","timestamp":1759744553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162031261X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S036030162031261X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.020","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}